Insights into Switching Schizophrenia Treatment from Invega Sustenna to UZEDY
Monday, 3 June 2024, 03:12
Insights into Switching Schizophrenia Treatment
Teva, in partnership with Medincell, presented new data offering valuable insights into transitioning patients with schizophrenia from Invega Sustenna to UZEDY.
Key Findings:
- Benefits: Highlighted potential benefits of switching medications
- Considerations: Discussed key considerations for patients and clinicians
The research adds to the growing body of knowledge surrounding schizophrenia treatment options, emphasizing the importance of individualized care.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.